title: Hematopoietic stem cell transplantation and implications for cell therapy reimbursement.
abstract: As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.
authors.affiliation: Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.forename: Dawn
authors.initials: D
authors.lastname: Driscoll
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000191:economics*; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000191:economics; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration